RXi Pharmaceuticals Appoints Peter Campochiaro M.D. To Its Scientific Advisory Board
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the appointment of Dr. Peter Campochiaro to its Scientific Advisory Board. Campochiaro is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience in the Johns Hopkins University School of Medicine. He is a prominent researcher, clinician and educator in the field of ophthalmology. He sees patients at the Wilmer Eye Institute at Johns Hopkins.
With more than 300 articles published in peer-reviewed medical journals, Dr. Campochiaro is a clinician-scientist who does both laboratory and clinical research. His major laboratory interest is in elucidating the molecular pathogenesis of ocular neovascularization and excessive vascular leakage. He has generated many animal models of retinal and choroidal vascular diseases that have been useful for evaluating drug and gene-based therapies. His laboratory helped to demonstrate the importance of vascular endothelial growth factor (VEGF) in retinal and choroidal vascular diseases and his clinical trial group performed many of the early phase studies evaluating VEGF antagonists. He serves on Scientific Advisory Board of several pharmaceutical companies.
"We are honored to have Dr. Campochiaro join our Scientific Advisory Board," said Dr. Pamela Pavco, Chief Development Officer of RXi Pharmaceuticals. "He brings a wealth of clinical research experience in ophthalmology to the Company that we will leverage to advance our ophthalmology program."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.